Form 8-K - Current report

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 17, 2024

 

AIM IMMUNOTECH INC.

(Exact name of registrant as specified in its charter)

 

Delaware		001-27072		52-0845822
(State or other jurisdiction		(Commission		(I.R.S. Employer
of incorporation)		File Number)		Identification No.)

 

2117 SW Highway 484, Ocala FL		34473
(Address of principal executive offices)		(Zip Code)

 

Registrant’s telephone number, including area code: [phone]

 

(Former name or former address, if changed since last report): N/A

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, par value $0.001 per share		AIM		NYSE American

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders

 

The 2024 Annual Meeting of Stockholders of AIM ImmunoTech Inc. (the “Company”) was held on December 17, 2024 (the “Annual Meeting”).

 

Set forth below are the matters voted upon at the Annual Meeting, which are more fully described in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on November 4, 2024, and the final voting results received from First Coast Results, Inc., the independent inspector of election for the Annual Meeting (the “Inspector of Election”).

 

As of the record date for the Annual Meeting, there were 63,706,446 shares of the Company’s common stock outstanding and entitled to notice of and to vote at the Annual Meeting. Of the record date shares, 34,441,399 shares, or 54%, were represented at the Annual Meeting either in person or by proxy, meaning the requisite quorum for the meeting of 40.0% was present.

 

The final tabulation from the Inspector of Election of voting results for the election of directors and other proposals presented at the Annual Meeting was as follows:

 

Proposal 1: Election of Directors:

 

Company Nominees:						Dissident Group Nominees Opposed by the Company:
		FOR		WITHHOLD				FOR		WITHHOLD
(1A) Stewart L. Appelrouth		16,644,896		17,208,517		(1E) Robert L. Chioini		15,086,016		18,767,100
(1B) Nancy K. Bryan		18,579,447		15,273,966		(1F) Todd A. Deutsch		15,251,249		18,601,867
(1C) Thomas K. Equels		17,410,488		16,442,925		(1G) Ted D. Kellner		16,966,423		16,886,693
(1D) William M. Mitchell		17,555,920		16,297,493		(1H) Paul W. Sweeney		15,959,390		17,893,726

 

Based on the final voting results reported by the Inspector of Election, the four directors elected at the Annual Meeting were Nancy K. Bryan, Thomas K. Equels, Ted D. Kellner and William M. Mitchell.

 

Proposal 2: Ratification of the selection of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024:

 

For: 23,702,823

Against: 1,843,749

Abstain: 8,894,827

 

Based on the final voting results reported by the Inspector of Election, Proposal 2 was approved.

 

Proposal 3: Approval, by non-binding advisory vote, of the compensation of the Company’s named executive officers:

 

For: 8,535,999

Against: 21,721,702

Abstain: 3,711,479

Broker Non Votes: 472,219

 

Based on the final voting results reported by the Inspector of Election, Proposal 3 was not approved.

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	AIM ImmunoTech Inc.
Date: December 20, 2024	By:	/s/ Thomas K. Equels
		Thomas K. Equels, CEO

 

 

Cover	Dec. 17, 2024
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Dec. 17, 2024
Entity File Number	001-27072
Entity Registrant Name	AIM IMMUNOTECH INC.
Entity Central Index Key	0000946644
Entity Tax Identification Number	52-0845822
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2117 SW Highway 484,
Entity Address, City or Town	Ocala
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	34473
City Area Code	(352)
Local Phone Number	448-7797
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	AIM
Security Exchange Name	NYSEAMER
Entity Emerging Growth Company	false

---